Delving into the Latest Updates on BNT-164a1 with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, mRNA vaccine

Synonyms

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication

Tuberculosis

Inactive Indication-

Originator Organization

BioNTech SE

Active Organization

BioNTech SE

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This is a two-part randomized, placebo-controlled, observer-blind, safety and dose-finding Phase Ib/IIa study. This study will evaluate up to four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedule.
This study includes: Part A (Phase Ib) and Part B (Phase IIa).

Start Date31 Jul 2023

Sponsor / Collaborator

BioNTech SE

NCT05537038

/ Active, not recruitingPhase 1

A Phase Ia, Randomized, Placebo-controlled, Double-blind, Dose-finding Evaluation Trial to Describe the Safety, Reactogenicity, and Immunogenicity of Two Investigational Vaccines Against Tuberculosis in IGRA-negative, BCG naïve Subjects

This randomized, placebo-controlled, double-blind, safety and dose-finding Phase Ia trial will evaluate four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedule.

Start Date18 Apr 2023

Sponsor / Collaborator

BioNTech SE

100 Clinical Results associated with BNT-164a1

Login to view more data

100 Translational Medicine associated with BNT-164a1

Login to view more data

100 Patents (Medical) associated with BNT-164a1

Login to view more data

100 Deals associated with BNT-164a1

Login to view more data